Integrated multi-omics reveals acylcarnitine accumulation as an early driver of doxorubicin-induced cardiotoxicity targeted by chlorogenic acid
Frontiers in Pharmacology · 30.07.2026 · 17
DOI: 10.3389/fphar.2026.1865654 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 30.07.2026. Verfasst von Jing Ren und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Introduction
Doxorubicin (DOX)-induced cardiotoxicity (DIC) is a major clinical challenge, with early metabolic reprogramming acting as a potential pathogenic driver. This study investigates the early lipid metabolic disturbances in DIC and evaluates the cardioprotective potential of the natural metabolic modulator, chlorogenic acid (CGA).
Methods
Transcriptomic analysis was utilized to identify initial metabolic alterations. Lipidomics and spatial metabolomics were performed to map lipid distributions in DOX-treated H9c2 cardiomyocytes and C57BL/6J mouse hearts. The therapeutic mechanisms of CGA were assessed in vivo through echocardiography and histopathology, and in vitro using pharmacological interventions targeting the PPAR-FAO axis.
Results
Transcriptomics and lipidomics revealed that DOX significantly suppresses the PPAR signaling pathway and fatty acid oxidation (FAO), resulting in the accumulation of ceramides and long-chain acylcarnitines. Spatial metabolomics confirmed in situ myocardial acylcarnitine accumulation. CGA treatment effectively improved cardiac function, mitigated oxidative stress, and inhibited apoptosis. Mechanistically, CGA reduced mitochondrial ROS and acylcarnitine levels by restoring PPAR expression and promoting FAO. Pharmacological blockade of PPARα or exogenous addition of acylcarnitines completely abolished CGA’s protective effects.
Discussion
Impaired FAO and the subsequent accumulation of toxic acylcarnitines serve as early drivers of DOX-induced metabolic dysfunction. Targeting this lipid metabolic dysregulation with CGA represents a promising therapeutic strategy for mitigating anthracycline-induced cardiotoxicity.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
- Institute for Translational Medicine, College of Medicine, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.
- Biomedical Center of Qingdao University, Qingdao, China.
Förderung
- Natural Science Foundation of Shandong Province
Zitieren
APA
Ren, J., Yang, Y., Li, G., Sha, H., Wang, B., Wang, Y., Cui, N., & Liu, T. (2026). Integrated multi-omics reveals acylcarnitine accumulation as an early driver of doxorubicin-induced cardiotoxicity targeted by chlorogenic acid. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1865654
Vancouver
Ren J, Yang Y, Li G, Sha H, Wang B, Wang Y, et al. Integrated multi-omics reveals acylcarnitine accumulation as an early driver of doxorubicin-induced cardiotoxicity targeted by chlorogenic acid. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1865654
BibTeX
@article{Ren2026,
author = {Ren, Jing and Yang, Yibo and Li, Guangdong and Sha, Huiying and Wang, Bing and Wang, Yin and Cui, Ning and Liu, Taoyan},
title = {Integrated multi-omics reveals acylcarnitine accumulation as an early driver of doxorubicin-induced cardiotoxicity targeted by chlorogenic acid},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1865654}
}
EUVIMED